查詢結果分析
來源資料
相關文獻
- 青光眼治療之新趨勢
- Carteolol (Arteoptic[feb9])之臨床評估及心血管作用--內因性擬交感神經作用之探討
- Timoptol-XE[feb9] 及Timoptol[feb9] 用於青光眼或高眼壓症病人之比較性研究
- 後房注射Alpha-chymotrypsin誘發之高眼壓兔眼模式之房水動力學變化
- Aqueous Inflow in Normal Tension Glaucoma
- 雷射虹膜穿孔術後眼壓控制不良之慢性隅角閉鎖性青光眼施予雷射小樑整形術之結果
- 低眼壓性青光眼之臨床研究
- Diurnal Variation of Intraocular Pressure in The Diagnosis And Management of Primary open-Angle Glaucoma
- Comparative Study of Timolol Gel Versus Timolol Solution for Patients with Glaucoma
- Effect of Mitomycin C for Combined Trabeculectomy and Phacoemulsification
頁籤選單縮合
| 題 名 | 青光眼治療之新趨勢=The Glaucoma Treatment Update |
|---|---|
| 作 者 | 呂大文; | 書刊名 | 國防醫學 |
| 卷 期 | 31:6 2000.12[民89.12] |
| 頁 次 | 頁612-619 |
| 專 輯 | 二十一世紀眼科學的新展望專輯 |
| 分類號 | 416.748 |
| 關鍵詞 | 青光眼; 眼壓; 細胞損傷; 神經保護; Glaucoma; Intraocular pressure; Cellular lnjury; Neuroprotection; |
| 語 文 | 中文(Chinese) |
| 中文摘要 | 長久以來青光眼一直被認為是因眼壓過高造成視神經盤病變與視野缺損而終致失明的一個疾患。但近年來的研究逐漸顯示,眼壓只是造成青光眼病理變化的致病因子之一,因為許多青光眼患者在眼壓降低之後,其視神經與視野變化仍持續進,因此造成青光眼病理變化的原因除了眼壓之外一定還有其他重要因子。 目前許多證據顯示「細胞損傷」可能是青光眼視神經盤病變的部份原因,有的學者甚至認為青光眼視神經盤病變是視網膜細胞死後亡後之共同途徑,因此若能拯救青光眼患者網膜節細胞之死亡,也許就能避免視神經盤病變之持續變化,此即視網膜神經保護觀念應用於青光眼治療之由來。 在本文中,對於青光眼治療之新趨勢,我們將之分為二部份,第一部份仍是針對傳統之治療方式,亦即眼壓有效降低著手;第二部份則是針對以視網膜神經保護為基礎以治療青光眼之現況與未來。 |
| 英文摘要 | For years, elevated intraocular pressure was believed to result in glaucoma, which subsequently caused optic disc neuropathy and visual field defects that eventually leaded to blindness. But recent evidence has shown that glaucoma optic neuropathy may be resulted from "cellular injury". So, if it is possible to rescue the retinal ganglion cell of glaucoma patients, the progression of optic neuropathy in glaucoma patients may be retarded. This is the so called "neuroprotection" concept in glaucoma treatment. There are three routes to protect the retinal ganglion cell under glaucoma condition. First, sufficient the blood supply of retina. Second, the use of neurotrophins, small molecules or gene therapy. Finally, induction of cell-rescue mechanisms. In this review, we will discuss the new trends for glaucoma therapy. The first part of this review emphasize on the modalities that used to lower intraocular pressure. The second part of this review will focus on neuroprotection and its application on glaucoma therapy. |
本系統中英文摘要資訊取自各篇刊載內容。